Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 MLN0264 in GCC-positive gastrointestinal carcinomas
jRCT2080222799Phase 2
- Sponsor
- Takeda
- Start
- Mar 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of indusatumab vedotin in abdominal malignancy, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Takeda.
02
Drugs
indusatumab vedotin
03
Conditions
abdominal malignancygastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222799.